Evinova

Digital transformation in clinical research remains one of the industry's toughest challenges.     Not because the technology is complex but implementing it at scale requires fundamental shifts in how teams work, collaborate, and make decisions.    In a recent Fierce Biotech webinar, industry leaders, including Evinova’s Chief Technology and Product Officer Sean Connolly, shared practical insights from real-world clinical development transformation efforts.    You can read the full recap on the Evinova blog → https://lnkd.in/ed_iJF8G

Clinical trial teams spend valuable time searching through hundreds of pages of protocol documentation just to find answers. That time adds up. We recently published results in ESMO Real World Data and Digital Oncology on the Study Document Assistant (SDA) — an AI-powered tool designed to surface answers directly from trial documents. In a controlled study, SDA delivered: ▪️ 43.8% faster responses to protocol queries ▪️ Maintained answer quality, validated by both experts and AI ▪️ High user satisfaction across teams When researchers spend less time navigating documentation, they spend more time advancing the trial. At Evinova, we build evidence-led AI-native solutions designed to accelerate clinical development and improve patient outcomes. Read the full publication to learn more:   https://lnkd.in/evSsZqBB Francesco Multari Kamen Bliznashki Ali Soltani Tehrani Maryam Khan #ClinicalTrials #AIinHealthcare #DigitalHealth

Our Head of Digital Health Consulting, Eoin Cassels, PhD, joined the #ClinicalTrialInnovationSummit last week for a panel on Unified Evidence in Clinical Trials: AI, Real-World Data, and Decentralized Innovation. The discussion got into the real complexities of decentralized clinical trials — what it takes to design and execute them well, how digital health technologies are reshaping site experience, and where AI is creating genuine opportunity in trial design and knowledge management. DCTs hold enormous promise for making trials more accessible and efficient, but only with the right evidence, the right design, and a clear-eyed view of the challenges. At Evinova, we're proud to contribute to these conversations as we work to accelerate clinical development through digital and AI-native innovation. #AIinClinicalDevelopment #Panagora

Is site technology alignment the missing piece in your clinical trial strategy? Discover key takeaways from Tufts Center for the Study of Drug Development and hear expert guidance on maximizing technology’s impact across sponsors, sites, and CROs. Don’t miss this strategic session. Why Level Setting around Site Technology May Be The Most Overlooked Step in Clinical Trial Planning Register here: https://lnkd.in/e3ambh7F    Jill Bell, Elisabeth Piault-Louis Beth Harper, Deena Bernstein

Cloud releases move fast. Attack surfaces move faster. In a recent ISMG Network interview, Evinova’s Adeeb M. discussed why we've moved from annual pen tests to AI-enabled continuous security validation and how traditional cybersecurity approaches need updating for today's cloud-native, fast-scaling health tech environment. When you're releasing software frequently, annual security testing creates dangerous gaps. Our approach now provides real-time visibility into our security posture, not outdated snapshots from months ago. For teams running regulated software in clinical research, this evolution is essential. Security validation needs to match the pace of development and deployment. This is just one of many ways Evinova upholds the highest standards in cybersecurity to protect our employees, customers and most importantly, patients. Check out the interview here: https://lnkd.in/e7YEGKZj #Cybersecurity #LifeSciences #ContinuousSecurity

Honored to be a finalist for the prestigious 2026 Prix Galien UK Award for Best Digital Health Solution! 🏆 Being recognized alongside the industry's most groundbreaking innovations for our Unified Trial Solution is incredible validation of the real-world impact we're delivering: ➡️ 60% improvement in patient experience (Nature Medicine published) ➡️ 32% cost reduction and 6-month+ acceleration in trial delivery ➡️ 50,000+ patients across 50+ countries with 9.1/10 usability ratings ➡️ Reduction in both duration and incidence of critical adverse events with our remote patient monitoring Congratulations to all the winners and fellow finalists! The innovation showcased last night proves we're in an exciting era for life science and especially clinical research. This recognition fuels our ambition to keep delivering AI-native technology that doesn't just digitize trials, but fundamentally transforms them around what sponsors, sites and patients truly need. #PrixGalien #ClinicalTrials #DigitalHealth The Galien Foundation Cristina Ortega Duran Gillian Bowden MBA Matthew Bonam Sean Connolly Jill Bell Paul O'Malley Dawn Plowman Nate Zhang Lauren Eardley

This Friday, Evinova’s Lisa Kerr, PhD, Senior Director of Patient Engagement will join an important discussion with ISPEP- The International Society for Patient Engagement Professionals on revolutionizing patient recruitment in clinical trials. See registration link in the comments. Patient recruitment remains one of the pharmaceutical industry's most persistent bottlenecks, directly impacting patient access to life-changing treatments and the quality of clinical data that drives medical breakthroughs. Lisa will be sharing insights from our collaborative project with ISPEP, demonstrating how meaningful partnerships and innovative, human-centered technology can transform this critical aspect of drug development. Looking forward to the discussion Emma Sutcliffe Steve Clark Amanda Decoker 📅 Friday, June 12th, 2026 🕐 4pm London | 11 am EST #ClinicalTrials #PatientRecruitment #DigitalHealth

We enjoyed the Digital Breakthrough for Pharma Summit yesterday at Bristol Myers Squibb, where our Chief Science Officer Jill Bell joined an expert panel about building regulatory confidence in digital endpoints.   A clear takeaway: getting digital endpoints right starts long before the technology.   ❓ Start with the clinical question, not the tool ↗️ Define endpoints that are meaningful for patients and decision-making ⚓ Anchor new measures to what regulators already understand 🏗️ Build data quality and integrity in from day one   At Evinova, we work with sponsors to define context of use and build the right evidence strategy upfront, enabling more confident, efficient regulatory engagement from the start.   Thanks for the great discussion Viprali Bhatkar, Ph.D.,Katie Jackson, Jacqueline Thong, Matteo Lai   #ClinicalDevelopment #DigitalEndpoints #RegulatoryScience